This techno-economic analysis/life-cycle assessment is based on actual production by the Cornell Marine Algal Biofuels Consortium with biomass productivity > 23 g/m 2-d. Ten distinct cases are presented for two locations, Texas and Hawaii, based on a 100-ha production facility with end-to-end processing that yields fungible co-products including biocrude, animal feed, and ethanol. Several processing technologies were evaluated: centrifugation and solvent extraction (POS Biosciences), thermochemical conversion (Valicor), hydrothermal liquefaction (PNNL), catalytic hydrothermal gasification (Genifuel), combined heat and power, wet extraction (OpenAlgae), and fermentation. The facility design was optimized by co-location with waste CO 2 , a terraced design for gravity flow, using renewable energy, and low cost materials. The case studies are used to determine the impact of design choices on the energy return on investment, minimum fuel and feed sale prices, discounted payback period, as well as water depletion potential, human health, ecosystem quality, non-renewable resources, and climate change environmental indicators. The most promising cases would be economically competitive at market prices around $2/L for crude oil, while also providing major environmental benefits and freshwater savings. As global demands for fuels and protein continue rising, these results are important steps towards economical and environmentally sustainable production at an industrial scale.

While timelines for clinical development have been extensively studied, there is little data on the broader path from initiation of research on novel drug targets, to approval of drugs based on this research. We examined timelines of translational science for 138 drugs and biologicals approved by the FDA from 2010–2014 using an analytical model of technology maturation. Research on targets for 102 products exhibited a characteristic (S-curve) maturation pattern with exponential growth between statistically defined technology initiation and established points. The median initiation was 1974, with a median of 25 years to the established point, 28 years to first clinical trials, and 36 years to FDA approval. No products were approved before the established point, and development timelines were significantly longer when the clinical trials began before this point (11.5 vs 8.5 years, p<0.0005). Technological maturation represents the longest stage of translation, and significantly impacts the efficiency of drug development.

Emiliania huxleyi, a ubiquitous marine algae, was cultured under replete and Cu-limiting conditions to investigate Cu uptake strategies involving thiols and associated redox reactions; comparisons to a model diatom, Thalassiosira pseudonana, were also drawn. Cu-limitation increased rates of cell surface reduction of Cu(II) to Cu(I) in E. huxleyi but not in T. pseudonana. Furthermore, Cu-limited E. huxleyi cells took up more Cu when cysteine was present compared to when no ligand was added, although a dependence on cysteine concentration was not observed. In contrast, Cu uptake by replete cells was dependent upon the relative abundance of inorganic species [Cu(I)']. We also show that cysteine can increase the bioavailability of Cu to Cu-limited cells, of both species, through the reductive release of Cu(I) from fairly strong Cu(II) ligands such as EDTA. Finally, support for a mechanism involving uptake of a Cys-Cu complex in E. huxleyi is drawn from the observation that Cu-limitation significantly enhances cysteine uptake by transporters that exhibit Michaelis-Menten kinetics. These Cu uptake strategies help explain the presence and distribution of dissolved thiols in surface seawater and have implications for the biogeochemical cycling of Cu in low Cu environments.

No abstract

No abstract